Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02276365
Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT02276391
Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment 1Drug: Treatment 2Drug: Treatment 3
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02276352
Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02276378
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02273388
- Locations
- 🇧🇪
1230.1.32002 Boehringer Ingelheim Investigational Site, Brussels, Belgium
🇧🇪1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Asasantin EROther: Standardized breakfast
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT02273492
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Asasantin ER (new formulation II - high)Drug: Asasantin ER (present commercial formulation)Drug: Asasantin ER (new formulation I - low)Drug: Asasantin ER (new formulation III - medium)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02273557
Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 54
- Registration Number
- NCT02273453
Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIIL 284 BS - rising doseDrug: Placebo
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT02273414
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02273440
© Copyright 2025. All Rights Reserved by MedPath